ATE248157T1 - Verbindungen und verfahren zur modulation von estrogen rezeptoren - Google Patents
Verbindungen und verfahren zur modulation von estrogen rezeptorenInfo
- Publication number
- ATE248157T1 ATE248157T1 AT99968578T AT99968578T ATE248157T1 AT E248157 T1 ATE248157 T1 AT E248157T1 AT 99968578 T AT99968578 T AT 99968578T AT 99968578 T AT99968578 T AT 99968578T AT E248157 T1 ATE248157 T1 AT E248157T1
- Authority
- AT
- Austria
- Prior art keywords
- methods
- disclosed
- compounds
- same
- modulating
- Prior art date
Links
- 102000015694 estrogen receptors Human genes 0.000 title abstract 4
- 108010038795 estrogen receptors Proteins 0.000 title abstract 4
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 208000000044 Amnesia Diseases 0.000 abstract 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 201000009273 Endometriosis Diseases 0.000 abstract 1
- 208000033830 Hot Flashes Diseases 0.000 abstract 1
- 206010060800 Hot flush Diseases 0.000 abstract 1
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
- 208000026139 Memory disease Diseases 0.000 abstract 1
- 206010027951 Mood swings Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 abstract 1
- 230000002411 adverse Effects 0.000 abstract 1
- 210000000988 bone and bone Anatomy 0.000 abstract 1
- 210000000481 breast Anatomy 0.000 abstract 1
- 210000000748 cardiovascular system Anatomy 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 230000002500 effect on skin Effects 0.000 abstract 1
- 239000003256 environmental substance Substances 0.000 abstract 1
- 229940011871 estrogen Drugs 0.000 abstract 1
- 239000000262 estrogen Substances 0.000 abstract 1
- 230000014509 gene expression Effects 0.000 abstract 1
- 230000003054 hormonal effect Effects 0.000 abstract 1
- 230000006984 memory degeneration Effects 0.000 abstract 1
- 208000023060 memory loss Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 210000002307 prostate Anatomy 0.000 abstract 1
- 201000004240 prostatic hypertrophy Diseases 0.000 abstract 1
- 230000001850 reproductive effect Effects 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 abstract 1
- 210000004291 uterus Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
- C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
- C07D311/18—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted otherwise than in position 3 or 7
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
- C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
- C07D311/16—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Reproductive Health (AREA)
- Child & Adolescent Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrane Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11447298P | 1998-12-30 | 1998-12-30 | |
| PCT/US1999/031290 WO2000039120A2 (en) | 1998-12-30 | 1999-12-30 | Compounds and methods for modulation of estrogen receptors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE248157T1 true ATE248157T1 (de) | 2003-09-15 |
Family
ID=22355427
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99968578T ATE248157T1 (de) | 1998-12-30 | 1999-12-30 | Verbindungen und verfahren zur modulation von estrogen rezeptoren |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP1140889B1 (de) |
| JP (1) | JP2002533456A (de) |
| KR (1) | KR100615757B1 (de) |
| CN (2) | CN100339374C (de) |
| AT (1) | ATE248157T1 (de) |
| AU (1) | AU765159B2 (de) |
| CA (1) | CA2356986A1 (de) |
| DE (1) | DE69910830T2 (de) |
| DK (1) | DK1140889T3 (de) |
| ES (1) | ES2207982T3 (de) |
| HK (1) | HK1041258B (de) |
| IL (2) | IL144003A0 (de) |
| PT (1) | PT1140889E (de) |
| WO (1) | WO2000039120A2 (de) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5877897A (en) | 1993-02-26 | 1999-03-02 | Donnelly Corporation | Automatic rearview mirror, vehicle lighting control and vehicle interior monitoring system using a photosensor array |
| US6822563B2 (en) | 1997-09-22 | 2004-11-23 | Donnelly Corporation | Vehicle imaging system with accessory control |
| US7655894B2 (en) | 1996-03-25 | 2010-02-02 | Donnelly Corporation | Vehicular image sensing system |
| US6331562B1 (en) | 1998-12-30 | 2001-12-18 | Signal Pharmaceuticals, Inc. | Compounds and methods for modulation of estrogen receptors |
| US6291456B1 (en) | 1998-12-30 | 2001-09-18 | Signal Pharmaceuticals, Inc. | Compounds and methods for modulation of estrogen receptors |
| US6593322B1 (en) | 1999-03-17 | 2003-07-15 | Signal Pharmaceuticals, Inc. | Compounds and methods for modulation of estrogen receptors |
| JP2003521468A (ja) | 1999-03-17 | 2003-07-15 | シグナル ファーマシューティカルズ, インコーポレイテッド | エストロゲンレセプタを変調させるための化合物及び方法 |
| KR20020075388A (ko) * | 1999-12-30 | 2002-10-04 | 시그널 파머슈티컬스 인크 | 에스트로겐 수용체의 조절 화합물 및 조절 방법 |
| EP1177787A3 (de) * | 2000-07-28 | 2003-09-10 | Pfizer Products Inc. | Verwendung von einem Östrogen Agonist/Antagonist zur Behandlung von Katarakt |
| HUP0401018A3 (en) | 2001-01-24 | 2007-05-29 | Chiesi Farma Spa | 2h-1-benzopyran derivatives, processes for their preparation and pharmaceutical compositions thereof |
| ES2236056T3 (es) * | 2001-01-24 | 2005-07-16 | Chiesi Farmaceutici S.P.A. | Derivados de 2h-1-benzopirano, procedimientos para su preparacion y composiciones farmaceuticas de los mismos. |
| EP1281710A1 (de) * | 2001-08-03 | 2003-02-05 | CHIESI FARMACEUTICI S.p.A. | 2H-1-Benzopyran derivat, Verfahren zur Herstellung und diese enthaltende pharmazeutische Zusammenstellungen |
| JP4358515B2 (ja) * | 2001-04-10 | 2009-11-04 | タカラバイオ株式会社 | 治療剤 |
| US7148252B2 (en) * | 2001-10-03 | 2006-12-12 | Signal Pharmaceuticals, Llc | Use of benzopyranones for treating or preventing a primary brain cancer or a brain metastasis |
| UA83620C2 (ru) | 2001-12-05 | 2008-08-11 | Уайт | Замещенные бензоксазолы и их аналоги как эстрогенные агенты |
| AU2003239155B2 (en) * | 2002-04-19 | 2008-12-04 | Novartis Ag | Benzopyranone compounds, compositions thereof, and methods of treatment therewith |
| AU2003225228A1 (en) | 2002-05-03 | 2003-11-17 | Donnelly Corporation | Object detection system for vehicle |
| US7091235B2 (en) * | 2002-10-15 | 2006-08-15 | Signal Pharmaceuticals, Llc | Benzopyranone compounds, compositions thereof, and methods for treating or preventing cancer |
| FR2849653B1 (fr) * | 2003-01-08 | 2006-08-25 | B F B Etudes Et Rech S Experim | Derives de la coumarine ayant une affinite pour les recepteurs aux estrogenes, procede pour leur preparation et compositions pharmaceutiques en contenant |
| CN1890235A (zh) | 2003-09-15 | 2007-01-03 | 西格诺药品有限公司 | 苯并吡喃酮化合物,其组合物以及用其进行治疗的方法 |
| US7526103B2 (en) | 2004-04-15 | 2009-04-28 | Donnelly Corporation | Imaging system for vehicle |
| WO2006078834A1 (en) * | 2005-01-21 | 2006-07-27 | Janssen Pharmaceutica N.V. | Novel heterocyclic benzo[c]chromene derivatives useful as modulators of the estrogen receptors |
| EP1899316A1 (de) * | 2005-06-24 | 2008-03-19 | Signal Pharmaceuticals LLC | Benzopyranonverbindungen zur behandlung von krebs |
| AR059339A1 (es) | 2006-02-09 | 2008-03-26 | Chugai Pharmaceutical Co Ltd | Derivados de la cumarina para trastornos proliferativos de celulas, composicion farmaceutica y agente terapeutico que los contiene |
| EP1860104A1 (de) * | 2006-05-22 | 2007-11-28 | Aptanomics | Von 3-Arylcoumarin oder 3-Arylchinolin-2-on abgeleitete antiproliferative Verbindungen und ihre Verwendung |
| CN101200460B (zh) * | 2007-11-19 | 2010-06-16 | 北京珅奥基医药科技有限公司 | 二氢苯并吡喃酮类化合物及其用途 |
| CN105541810B (zh) * | 2016-03-04 | 2019-05-17 | 南京工业大学 | 一种香豆素类nedd8激活酶抑制剂及其制备方法与应用 |
| CN105801543B (zh) * | 2016-04-18 | 2019-08-02 | 中国药科大学 | 4-芳香胺-香豆素衍生物及其制备方法和医药用途 |
| CN105801544A (zh) * | 2016-04-18 | 2016-07-27 | 中国药科大学 | 3-芳基-4-芳香胺-香豆素衍生物及其制备方法和医药用途 |
| CN112426420B (zh) * | 2020-12-01 | 2021-12-28 | 浙江大学 | 香豆素-二硫代氨基甲酸酯衍生物在制备抗肿瘤药物中的应用 |
| CN112645922B (zh) * | 2020-12-24 | 2022-01-07 | 中国人民解放军空军军医大学 | 香豆素类化合物、制备方法及应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2857401A (en) * | 1956-12-20 | 1958-10-21 | Searle & Co | Acetylated coumarin derivatives |
| DE4323409A1 (de) * | 1993-07-13 | 1995-01-19 | Boehringer Mannheim Gmbh | Verwendung von Cumarinen und Carbostyrilen als PLA¶2¶-Inhibitoren, neue Cumarine und Carbostyrile, Verfahren zu ihrer Herstellung und Arzneimittel |
| JPH10513470A (ja) * | 1995-02-06 | 1998-12-22 | イーライ・リリー・アンド・カンパニー | Il−6の効果を阻害する方法 |
| ES2188908T3 (es) * | 1996-10-28 | 2003-07-01 | Novo Nordisk As | Derivados de cis-3,4-cromano utiles para la prevencion o tratamiento de sindromes relacionados con el estrogenos. |
| ZA979645B (en) * | 1996-10-28 | 1998-04-28 | Novo Nordisk As | Heterocyclic compounds, compositions and uses. |
| JP2001502711A (ja) * | 1996-10-28 | 2001-02-27 | ノボ ノルディスク アクティーゼルスカブ | エストロゲン関連疾患又は症候群の予防又は治療において有用な新規のシス―3、4―クロマン誘導体 |
| ZA979644B (en) * | 1996-10-28 | 1998-04-28 | Novo Nordisk As | Heterocyclic compounds, compositions and uses. |
| IL129622A0 (en) * | 1996-10-28 | 2000-02-29 | Novo Nordisk As | Novel CIS-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes |
| EP0937059A1 (de) * | 1996-10-28 | 1999-08-25 | Novo Nordisk A/S | $i(TRANS)-3,4-CHROMANDERIVATE ZUR VORBEUGUNG ODER BEHANDLUNGVON OESTROGENBEZOGENEN KRANKHEITEN ODER SYNDROMEN |
-
1999
- 1999-12-30 CA CA002356986A patent/CA2356986A1/en not_active Abandoned
- 1999-12-30 IL IL14400399A patent/IL144003A0/xx active IP Right Grant
- 1999-12-30 AU AU25970/00A patent/AU765159B2/en not_active Ceased
- 1999-12-30 KR KR1020017008410A patent/KR100615757B1/ko not_active Expired - Fee Related
- 1999-12-30 ES ES99968578T patent/ES2207982T3/es not_active Expired - Lifetime
- 1999-12-30 CN CNB2004100422993A patent/CN100339374C/zh not_active Expired - Fee Related
- 1999-12-30 EP EP99968578A patent/EP1140889B1/de not_active Expired - Lifetime
- 1999-12-30 DK DK99968578T patent/DK1140889T3/da active
- 1999-12-30 WO PCT/US1999/031290 patent/WO2000039120A2/en not_active Ceased
- 1999-12-30 DE DE69910830T patent/DE69910830T2/de not_active Expired - Fee Related
- 1999-12-30 AT AT99968578T patent/ATE248157T1/de not_active IP Right Cessation
- 1999-12-30 HK HK02101413.5A patent/HK1041258B/en not_active IP Right Cessation
- 1999-12-30 PT PT99968578T patent/PT1140889E/pt unknown
- 1999-12-30 CN CNB998163740A patent/CN1155589C/zh not_active Expired - Fee Related
- 1999-12-30 JP JP2000591031A patent/JP2002533456A/ja active Pending
-
2001
- 2001-06-26 IL IL144003A patent/IL144003A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| KR100615757B1 (ko) | 2006-08-25 |
| HK1075893A1 (zh) | 2005-12-30 |
| CN1597677A (zh) | 2005-03-23 |
| CN1155589C (zh) | 2004-06-30 |
| ES2207982T3 (es) | 2004-06-01 |
| DK1140889T3 (da) | 2003-12-22 |
| IL144003A0 (en) | 2002-04-21 |
| KR20010101346A (ko) | 2001-11-14 |
| WO2000039120A2 (en) | 2000-07-06 |
| JP2002533456A (ja) | 2002-10-08 |
| DE69910830T2 (de) | 2004-06-17 |
| CN1337958A (zh) | 2002-02-27 |
| CA2356986A1 (en) | 2000-07-06 |
| IL144003A (en) | 2006-07-05 |
| DE69910830D1 (de) | 2003-10-02 |
| EP1140889B1 (de) | 2003-08-27 |
| AU2597000A (en) | 2000-07-31 |
| AU765159B2 (en) | 2003-09-11 |
| HK1041258A1 (en) | 2002-07-05 |
| CN100339374C (zh) | 2007-09-26 |
| PT1140889E (pt) | 2004-01-30 |
| EP1140889A2 (de) | 2001-10-10 |
| WO2000039120A3 (en) | 2000-10-26 |
| HK1041258B (en) | 2003-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE248157T1 (de) | Verbindungen und verfahren zur modulation von estrogen rezeptoren | |
| ATE289300T1 (de) | Verbindungen und verfahren zur modulation von estrogen rezeptoren | |
| WO2000055137A8 (en) | Compounds and methods for modulation of estrogen receptors | |
| ATE355279T1 (de) | Pyrazole als modulatoren des östrogenrezeptors | |
| Lecanda et al. | Gap junctional communication modulates gene expression in osteoblastic cells | |
| ES2172579T3 (es) | Agonistas/antagonistas de estrogenos. | |
| AU5467699A (en) | Substituted isoxazole as estrogen receptor modulators | |
| MY112949A (en) | Benzo-thiaphene estrogen agonists to treat prostatic hyperplasia | |
| DE69838177D1 (de) | Androgensyntheseinhibitoren | |
| CY1115317T1 (el) | Εκλεκτικος ρυθμιστης οιστρογονικου υποδοχεα σε συνδυασμο με δεϋδροεπιανδροστερονη (dhea) ή αναλογα | |
| ATE148331T1 (de) | Vorrichtung zum produzieren von knochenzement zur fixierung von prothesen | |
| ATE292468T1 (de) | Verwendung von biogenen estrogensulfamaten zur hormonsubstitutionstherapie | |
| DE69603827D1 (de) | Waisen-rezeptor | |
| TR200003377T2 (tr) | Estrojenler ile bütünleşik 2-fenil-1-[4-(2-aminoetoksi)benzil]-indol | |
| NO20000579L (no) | Heparin-bindende vekstfaktor (HBGF) -polypeptider | |
| BR0110087A (pt) | Compostos para modular proliferação celular | |
| NO984631D0 (no) | <alfa>1-Adrenerge reseptor-antagonister | |
| Friedman | The Estradiol-Dihydrotestosterone model of prostate cancer | |
| DE69720620D1 (de) | 8-Substituierte B-nor-6-Thiaequilin Verbindungen als selektiven Östrogenrezeptormodulatoren | |
| DK1196428T3 (da) | 11-beta-aryl-17,17-spirothiolan-substituerede steroider | |
| ES2155911T3 (es) | Derivados de alcanfor como nuevos odorantes. | |
| MY137604A (en) | Benzopyranone compounds, compositions thereof, and methods of treatment therewith | |
| Charnock-Jones et al. | Vascular endothelial growth factor and corpus luteum angiogenesis | |
| Meyers | The role of hormone receptors in estrogen activity is questionable | |
| KR980000154A (ko) | 홍화씨를 주재로한 신규한 식품소재 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1140889 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |